Tigecycline GI Adverse Events Incidence
Tigecycline, an intravenous glycylcycline antibiotic, commonly causes gastrointestinal (GI) side effects, primarily nausea and vomiting. In clinical trials across approved indications (skin/soft tissue infections, intra-abdominal infections, community-acquired pneumonia), nausea occurred in 26% of patients and vomiting in 18%.[1][2] These rates are higher than with comparators like vancomycin or imipenem (nausea ~10-15%, vomiting ~8-12%).[1]
Discontinuation due to GI events happens in about 4-7% of cases, mostly from nausea/vomiting.[2]
Nausea and Vomiting Breakdown
- Nausea: 19-35% overall; peaks at 35% in complicated intra-abdominal infections.[1][2]
- Vomiting: 13-26%; similar pattern across indications.[1]
- Onset is typically early (first 1-2 days of infusion) and dose-related; slower infusion (over 120 minutes) reduces incidence by ~20-30%.[3]
Diarrhea affects 12-20%, often mild and self-limiting.[2]
Comparison to Other Antibiotics
Tigecycline's GI events exceed those of beta-lactams or fluoroquinolones (nausea <10%) but align with some tetracyclines. In head-to-head trials:
| Drug | Nausea % | Vomiting % |
|------|----------|------------|
| Tigecycline | 26 | 18 |
| Imipenem | 15 | 10 |
| Levofloxacin | 8 | 6 |[1][2]
This higher rate stems from tigecycline's biliary excretion and gut microbiome disruption.[3]
Risk Factors and Management
Higher risk in elderly patients (>65 years: nausea 30% vs. 23% overall) and those with hepatic impairment.[2] Prophylactic antiemetics (e.g., ondansetron) cut nausea by 40-50% in studies.[3]
No direct link to DrugPatentWatch.com for GI data, as tigecycline (Tygacil) generics entered post-2021 patent expiry.[4]
Sources
[1] FDA Tygacil Label (2010)
[2] Clinical Review: Safety Profile (2009)
[3] Infusion Rate Impact (2009)
[4] DrugPatentWatch: Tygacil Patents